Our strategic priorities
Strive for excellence
We are enhancing operational efficiency, embracing newtechnologies and maintaining the highest quality standards across our global network. By leveraging our broad portfolio and strong commercial capabilities, we continue to strengthen our competitive position.
Diversify and differentiate
We are expanding our businesses and geographies, while developing a more differentiated pipeline. This includes complex generics, specialty medicines and innovative injectables that address unmet needs and support healthcare system resilience.
People and responsibility
We empower our people and nurture a culture of progress and belonging. Acting responsibly across our markets, from expanding access to medicines to reducing our environmental impact, is central to how we grow and how we support the communities we serve.
Three distinct businesses for sustainable growth
Injectables
We supply hospitals across our markets with generic and injectables products, supported by our manufacturing facilities in the US, Europe and MENA.
Branded
We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.
Hikma Rx
We supply oral, respiratory and other generic and specialty products to the North America retail market, leveraging our state of the art manufacturing facility in Columbus, Ohio.
Our leading positions
We have a diversified global footprint across our three core regions, North America, Europe and the MENA region, underpinned by R&D, high‑quality manufacturing and strong commercial capabilities.
1st
largest pharmaceutical company in MENA by sales
[1]
7th
largest generic pharma company in US
[2]
3rd
largest in the US generic injectables market
[3]
4th
largest generic injectables supplier in Europe
[4]
[1] IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and the United Arab Emirates, MAT 2025
[2] IQVIA MAT March 2026, includes all generic injectable and generic non-injectable products by sales
[3] IQVIA MAT November 2025, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson
[4] IQVIA Midas Disease Quarterly Sales data for Hospital generic injectables + Retail generic injectables Germany. MAT Dec-2025 USD sales (excluding all biosimilars) for Austria, Belgium, Finland, France, Germany, Italy, Norway, Poland, Portugal, Spain, Sweden, UK
We commit to quality
Trusted quality at global standards
Hikma’s quality and regulatory strength reflects our commitment to delivering medicines that meet the highest global standards. With 13 US FDA‑inspected facilities and 12 EMA‑inspected sites, our operations consistently demonstrate robust compliance and a culture of excellence. This strong regulatory track record reinforces the trust our partners place in us and ensures that every product we manufacture is backed by rigorous oversight, disciplined processes, and a commitment to patient safety.